Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N J Meropol

Showing results (31-40 of 69) with videos related to

Pageof 7
Sort By:
Cancer|January 1, 1995
Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trialB N Stein, N J Petrelli, H O Douglass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancerN Soni, N J Meropol, L Pendyala, et al.
Investigational New Drugs|January 1, 1996
Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancerR Pazdur, N J Meropol, E S Casper, et al.
The Journal of Biological Chemistry|July 15, 1992
Requirement of hydrophilic amino-terminal residues for granulocyte-macrophage colony-stimulating factor bioactivity and receptor bindingN J Meropol, S W Altmann, A B Shanafelt, et al.
Journal of the National Cancer Institute|August 5, 1992
Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapyN J Meropol, L L Miller, E L Korn, et al.
Investigational New Drugs|January 1, 1997
Unusual central nervous system toxicity in a phase I study of N1N11 diethylnorspermine in patients with advanced malignancyP J Creaven, R Perez, L Pendyala, et al.
Cancer Investigation|May 4, 1999
Prognostic factors affecting survival in patients with colorectal carcinomatosisE A Marcus, T K Weber, M A Rodriguez-Bigas, et al.
Seminars in Oncology|December 1, 1996
Early phase studies with paclitaxel/low-dose carboplatin in patients with solid tumorsP J Creaven, D Raghavan, R P Perez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 29, 2006
A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200B J Giantonio, D E Levy, P J O'dwyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2000
Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathioneL Pendyala, P J Creaven, G Schwartz, et al.
Pageof 7

Showing results (31-40 of 69) with videos related to

Sort By:
Pageof 7
Cancer|January 1, 1995
Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trialB N Stein, N J Petrelli, H O Douglass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancerN Soni, N J Meropol, L Pendyala, et al.
Investigational New Drugs|January 1, 1996
Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancerR Pazdur, N J Meropol, E S Casper, et al.
The Journal of Biological Chemistry|July 15, 1992
Requirement of hydrophilic amino-terminal residues for granulocyte-macrophage colony-stimulating factor bioactivity and receptor bindingN J Meropol, S W Altmann, A B Shanafelt, et al.
Journal of the National Cancer Institute|August 5, 1992
Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapyN J Meropol, L L Miller, E L Korn, et al.
Investigational New Drugs|January 1, 1997
Unusual central nervous system toxicity in a phase I study of N1N11 diethylnorspermine in patients with advanced malignancyP J Creaven, R Perez, L Pendyala, et al.
Cancer Investigation|May 4, 1999
Prognostic factors affecting survival in patients with colorectal carcinomatosisE A Marcus, T K Weber, M A Rodriguez-Bigas, et al.
Seminars in Oncology|December 1, 1996
Early phase studies with paclitaxel/low-dose carboplatin in patients with solid tumorsP J Creaven, D Raghavan, R P Perez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 29, 2006
A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200B J Giantonio, D E Levy, P J O'dwyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2000
Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathioneL Pendyala, P J Creaven, G Schwartz, et al.
Pageof 7